An Alzheimer's vaccine may stop the build-up of both types of toxic plaques and tangles, Diamondra's sufferer's intelligence, a new study suggests. `
Scientists at the University of Texas, Southwestern, develop a shot that uses DNA from Alzheimer's proteins to study the immune system to fight the compounds and keep them from accumulating in the brain.
Their vaccine is not the first attempt to delay the progression of Alzheimer's, but the UT Southwestern team's dose is delivered in the skin and does not appear to cause the harmful brain swelling that other shots have.
The researchers believe that they are closing on a human project for their preventive shot.
Every 65 seconds, another United States develop Alzheimer's, and the number of sufferers is expected to be more than tripled by 2050.
In the last few years, we have discovered more of the risk factors for dying brain disease, but there is no cure to prevent Alzheimer from developing and minimally treatments for its symptoms.
Primary doses of Alzheimer's therapies include two types of proteins: Beta-Amoiloid and Tau.
As we age, our biological process begins to get a little sloppy.
So beta-amoioid proteins start getting misfolded in lumpy shapes that stick together and interrupt the neural connections.
Similarly, TA proteins, which are stringier in shape, start getting tangled.
The two spots of neurological messiness are the hormones of Alzheimer's development, so scientists believe that if they can slow down or stop the inelastic form of forming, they may be able to slow down or even stop diamania.
Dr. Roger Rosenberg, a founding director of the Alzheimer's Disease Center at Texas Southwestern University, is among the attempts to boost the immune system's power to attack the plausible plaques and tangles.
The new study, he says, is the culmination of a decade of research that repeatedly demonstrated that this vaccine can effectively and safely target in animal models that we think may cause Alzheimer's disease.
I believe we get close to testing the therapy in people.
The vaccine contains a DNA coding for a segment of beta-amoioid – which also reduces Tau – in mice modeling to have Alzheimer's disease.
Its DNA content act as a training target for the immune system that teaches to identify the two proteins and attack them when they begin to build themselves.
A similar line of work, taken by another institution in the early 2000's, has effectively increased the immune system against the plaques and tangles, but it caused a whole new problem, as the immune response triggered a severe brain swelling.
The new vaccine seems to activate the immune system, but in a different way that the swelling can circulate, and may be safe for humans, according to the new findings, published in the magazine Alzheimer's research and therapy.
Robberberg's Lab has demonstrated a similar response in rabbits and monkeys in previous work.
It helped to put the vaccine he and his team were developing in a short list of promising antibody treatments for Alzheimer's disease.
Follow NEWS.am drug on Facebook and Twister